The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.
 
Sindhu Vikash
No Relationships to Disclose
 
Fnu Vikash
No Relationships to Disclose
 
Ansh Mehta
No Relationships to Disclose
 
Fernand Bteich
No Relationships to Disclose
 
Rama Al Hamed
No Relationships to Disclose
 
Karun Neupane
No Relationships to Disclose
 
Abdul-Hamid Bazarbachi
No Relationships to Disclose
 
M Bakri Hammami
No Relationships to Disclose
 
Stepan M. Esagian
No Relationships to Disclose
 
Hiba Narvel
No Relationships to Disclose
 
Eleftheria Atalla
No Relationships to Disclose
 
Charan Thej Reddy Vegivinti
No Relationships to Disclose
 
Rajvi Gor
No Relationships to Disclose
 
Nishi Shah
No Relationships to Disclose
 
Aditi Shastri
No Relationships to Disclose
 
Ulrich G Steidl
No Relationships to Disclose
 
Amit Verma
No Relationships to Disclose
 
Alejandro R. Sica
No Relationships to Disclose
 
Andreas Kaubisch
No Relationships to Disclose
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - Amgen; Merck
Research Funding - BeiGene (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); PharmaMar (Inst); Takeda (Inst); TLC PharmaChem (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364